Program Information


Tuesday, 13 October 2020

On-site Registration & Welcome Hors d’Oeuvres

15:30 – 16:00
Panel Discussions/Q&A SESSION
16:00 – 17:00



Radisson Blu Hotel
Hall Alfa
Vilnius, Lithuania


CUTTING-EDGE INSIGHTS
While attending EADO 2020, please join our faculty as they address pressing questions about unresectable cutaneous squamous cell carcinoma (CSCC). Using real-world patient cases, they will demonstrate how and when to safely incorporate new and emerging immune checkpoint inhibitors into your practice for patients in whom surgery may not be an option.


SYMPOSIUM AGENDA

15:30 – 16:00
 
On-site Registration & Welcome Hors d’Oeuvres
16:00 – 16:10
 
Opening Remarks & Introductions
Badri Modi, MD
16:10 – 16:30
 
Panel Discussion 1 –
Immunotherapy in Advanced CSCC: Rationale

All Faculty
16:30 – 16:50
 
Panel Discussion 2 –
Incorporating Immunotherapy into Practice:
Safety, Patient Selection, and Emerging Therapies

All Faculty
16:50 – 17:00
 
Closing Remarks & Audience Questions
All Faculty

Badri Modi, MD (Chair)
Assistant Clinical Professor
Division of Dermatology
City of Hope
Duarte, CA, USA

Irene Braña, MD, PhD
Clinical Investigator
Molecular Therapeutic Research Unit and ENT Unit
Vall d’Hebron University Hospital
Vall d’Hebron Institute of Oncology (VHIO)
Barcelona, Spain
Victor Moreno, MD, PhD
Director, Early Phase Clinical Trials Unit
START Madrid-FJD, Hospital Fundación Jiménez Díaz
Madrid, Spain


EDUCATIONAL OBJECTIVES
After completing this activity, the clinician should be better able to:

  • Effectively identify CSCC and assess risk of developing advanced disease
  • Delineate the safety and efficacy of immunotherapeutic agents for CSCC
  • Effectively manage immune-mediated adverse reactions associated with the mechanism of action of checkpoint inhibitors
  • Select therapy for individual patients according to current evidence and guidelines, offering clinical trial enrollment where appropriate

TARGET AUDIENCE
Oncology, dermatology, and dermato-oncology clinicians who manage patients with cutaneous squamous cell carcinoma (CSCC).


PROVIDER STATEMENT
This educational activity was independently developed by RMEI Medical Education, LLC in collaboration with Advancing Knowledge in Healthcare (AKH) Inc. All faculty and planner conflicts of interest were identified and resolved and AKH has reviewed the content and determined it to be fair, balanced, and without commercial bias.


STATEMENT OF SUPPORT
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme.


FEE STATEMENT
There is no fee for this educational activity.


QUESTIONS?
Please contact Stephanie Kielt at skielt@rmei.com if you have any questions.




FOLLOW RMEI
Facebook  Twitter  RMEI Twitter

Additional educational activities offered by RMEI Medical Education, LLC can be found
at www.RMEI.com or by calling toll-free (866) 770-RMEI.